A double-blind comparison of topical therapy of chlamydial ocular infection (TRIC infection) with rifampicin or chlortetracycline

S. DAROUGAR, N. VISWALINGAM, H. EL-SHEIKH, P. A. HUNTER, and P. YEARSLEY

From the External Eye Diseases Clinic, Moorfield's Eye Hospital, City Road, London EC1V 2PD, and the Subdepartment of Virology, Institute of Ophthalmology, Judd Street, London WC1H 9QS

SUMMARY A double-blind stratified trial was carried out on 85 patients to assess the efficacy of topical therapy with 1% chlortetracycline eye ointment in comparison with 1% rifampicin eye ointment in the treatment of chlamydial ocular infection of sexually transmitted origin (paratrachoma). Patients included were selected on the basis of positive culture for Chlamydia trachomatis. A 6-week course of treatment with chlortetracycline or rifampicin 3 times daily gave a clinical cure rate of 80% and 75% and a microbiological cure rate of 93% and 86%, respectively. In patients who were not cured the intensity of inflammatory responses was considerably reduced.

Chlamydia ocular infection of sexually transmitted origin (paratrachoma or TRIC ocular infection) is becoming commoner in the urban populations of both developed and developing countries. This is because of a substantial increase in the incidence of chlamydial genital infections, that is, chlamydial urethritis and chlamydial cervicitis.

In a previous paper it was shown that topical therapy of paratrachoma with rifampicin eye ointment produced a clinical and microbiological cure rate of 90%. In this paper we present the result of a double-blind stratified trial to assess the efficacy of topical therapy of paratrachoma with rifampicin eye ointment compared with chlortetracycline eye ointment.

Subjects and methods

Selection of patients. Patients attending the External Eye Diseases Clinic, Moorfield's Eye Hospital, with acute follicular conjunctivitis and a positive culture for Chlamydia trachomatis were selected. Excluded from this study were patients who had symptoms of concurrent genital infection, or who had been treated with antibiotics known to be effective against Chlamydia, or who were unable to attend for 12 weeks after the initial visit.

Clinical examination. Patients were examined with a Haag-Streit slit-lamp. The symptoms and signs in the conjunctiva of the upper tarsus, upper fornix, and lower lid and cornea were graded on a 0 to 3 scale as described previously. The severity of disease was calculated from an extension of the scoring system used for trachoma.

Laboratory investigations. The methods of collection of conjunctival swabblings, transport to the laboratory, culture in irradiated McCoy cells, and identification of isolates have been described elsewhere.

Random allocation. Patients included in the study were allocated to treatments by the Chief Pharmacist, Moorfield's Eye Hospital, according to a randomisation schedule stratified for age, sex, intensity of conjunctival inflammatory responses, and corneal involvement.

Medication. Each patient was treated with either 1% chlortetracycline eye ointment or 1% rifampicin eye ointment 3 times daily for 6 weeks. The antibiotics were supplied by Le Petit Pharmaceuticals Ltd in identical containers each labelled with a code number. Patients were requested to avoid using the eye ointment on the day they attended the clinic, until after they were examined. This was to prevent any biased observation which could occur.
Table 1  Numbers of patients cured after treatment with chlortetracycline or rifampicin eye ointment

<table>
<thead>
<tr>
<th>Drug</th>
<th>No. of patients</th>
<th>8 Weeks Clinical</th>
<th>8 Weeks Microbiological</th>
<th>12 Weeks Clinical</th>
<th>12 Weeks Microbiological</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlortetracycline</td>
<td>41</td>
<td>36 (88%)</td>
<td>39 (95%)</td>
<td>33 (80%)</td>
<td>38 (93%)</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>44</td>
<td>34 (77%)</td>
<td>40 (91%)</td>
<td>33 (75%)</td>
<td>38 (86%)</td>
</tr>
</tbody>
</table>

because of the red colour of rifampicin eye ointment.

Follow-up investigations. After the initial clinical and laboratory investigations, treatment was started and follow-up investigations were carried out at weekly intervals for 4 weeks, then at 6, 8, and 12 weeks. After the last visit all patients were referred to the Diagnostic Clinic, Moorfield's Eye Hospital, for further investigation and treatment of chlamydial genital infection.

Statistical analysis. Chi-squared significance tests were used for comparison of results.

Results

Eighty-five patients suffering from inclusion conjunctivitis or TRIC punctate keratoconjunctivitis were included in this study. The numbers of males and females were 53 to 32. Their ages ranged between 15 and 48 years, the majority being 20 to 30 years old.

The clinical and microbiological findings in 41 patients treated with chlortetracycline and 44 patients treated with rifampicin are shown in Table 1 and Figs. 1 and 2.

The average clinical scores before treatment in the groups treated with chlortetracycline or rifampicin were 34 and 36 respectively. After 1 week of treatment there was a marked decrease in the clinical scores in both groups of patients (Fig. 1). The average clinical scores in these patients immediately after completion of treatment at 6 weeks was 8 for chlortetracycline and 9 for rifampicin (Fig. 1). Clinical examination at 12 weeks showed complete cure in 33 out of 41 (80%) of patients treated with chlortetracycline and 33 out of 44 (75%) of patients treated with rifampicin (Table 1). The beneficial effects of therapy with the 2 antibiotics were statistically significant (p < 0.001), but there was no difference in the efficacy of the 2 drugs (p > 0.2). There was a marked improvement in the clinical condition of the patients who were not cured by chlortetracycline or rifampicin therapy. At the last examination of the 8 patients not cured with chlortetracycline 2 had moderate disease and 6 had mild disease. Microbiologically 3 of these 8 patients were positive. Of the patients who were not cured by rifampicin therapy 2 had severe disease, 2 had moderate disease, and 7 had mild disease at the last clinical examination. Microbiologically 6 of these 11 patients were positive.

There was a considerable drop in the numbers of isolation-positive patients at 1 week; only 4 (10%) out of 41 patients treated with chlortetracycline and 1 (2%) out of 44 treated with rifampicin were

Fig. 1  Changes in the average score of intensity of signs and symptoms after treatment with chlortetracycline (●) or rifampicin (■).
positive (Fig. 2). At 6 weeks follow-up, immediately after completion of treatment, 1 patient treated with chlortetracycline was positive, and 2 patients treated with rifampicin were positive. At 12 weeks follow-up the numbers of patients positive for C. trachomatis were 3 (7%) and 6 (14%) for chlortetracycline and rifampicin respectively (Fig. 2). All these positive patients showed active clinical signs.

Discussion

In this double-blind treatment trial stratified randomisation for grades and intensity of inflammatory responses, age, and sex produced a well balanced distribution of patients in groups allocated to treatment with chlortetracycline or rifampicin.

In the present study the whole conjunctiva including the upper tarsal area was examined for assessing the presence and intensity of inflammatory changes. This was done because the results of clinical and therapeutic studies of trachoma and paratrachoma have shown: (a) in the whole conjunctiva the intensity of inflammatory responses is higher than in the upper tarsal conjunctiva; (b) after treatment the cure rate for the whole conjunctiva is markedly lower than the rate for the upper tarsal conjunctiva; and (c) in some patients with cured upper tarsal conjunctiva an active but mild to moderate disease could be found in the upper and lower conjunctival fornices. It was found that this residual disease can cause recurrence in treated patients.

In this study the follow-up investigations were carried out for up to 6 weeks after completion of treatment. This was done because in a previous study of topical therapy of paratrachoma with rifampicin eye ointment we found that clinical and microbiological recurrences generally occur within 6 weeks after completion of treatment.

The results of this investigation show that topical therapy of paratrachoma with chlortetracycline or rifampicin eye ointment, 3 times daily for 6 weeks, is highly effective (Table 1). Rifampicin produced clinical and microbiological cure rates of 75% and 86% respectively. These rates are similar to those obtained in a previous study. Chlorotetracycline also produced very high clinical and microbiological cure rates of 80% and 93% respectively. Although this regimen of therapy has been recommended as a standard method of treatment of paratrachoma, we have not found any well-documented reports to support its efficacy.

In the present trial between 20 and 25% of patients were not cured clinically after treatment with either chlortetracycline or rifampicin (Table 1). Although an initial clinical improvement was observed in all these patients, moderate to severe recurrences were observed in only 2 patients (5%) treated with chlortetracycline and 4 patients (9%) treated with rifampicin. While it is possible that drug resistance may have developed in these cases, we have made no attempt to investigate this. In a previous study we found that resistance to rifampicin had not developed in C. trachomatis isolates obtained from patients who were not cured with this
drug. We suggest therefore that inadequate application of eye ointment may be responsible for these failures, although there was no evidence of default in the frequency of application of ointment.

The authors are grateful to colleagues at Moorfield’s Eye Hospital for referring their patients and to Mr R. Watkins, Chief Pharmacist, Moorfield’s Eye Hospital, for organising the random allocation of patients.

This work was financially supported by the Locally Organised Clinical Research Scheme, Moorfield’s Eye Hospital, and by a grant from the Department of Health and Social Security and an anonymous donor.

References


